CIK 0001651308 · Large accelerated filer
BeOne Medicines Ltd.
Sign in to watch- Ticker
- BEIGF
- Exchange
- Nasdaq, OTC
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 981209416
- Phone
- 41-616851900
- Business address
- C/O BEONE MEDICINES I GMBH, AESCHENGRABEN 27, 21ST FLOOR, BASEL, Switzerland, 4051
- Former names
- BeiGene, Ltd.
Securities
- ONC American Depositary Shares Nasdaq
- BEIGF Common stock OTC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $48,487,541
- in 9 filings, $47.8M under 10b5-1 plans
Net −$48,487,541. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-03-18 | Wang Xiaodong Director | Option exercise 10b5-1 | +41,760 | $6.50 | $271K | 41,760 |
| 2025-03-18 | Wang Xiaodong Director | Sale 10b5-1 | −2,417 | $258.25 | $624K | 39,343 |
| 2025-03-18 | Wang Xiaodong Director | Sale 10b5-1 | −6,926 | $259.08 | $1.8M | 32,417 |
| 2025-03-18 | Wang Xiaodong Director | Sale 10b5-1 | −2,694 | $259.86 | $700K | 29,723 |
| 2025-03-18 | Wang Xiaodong Director | Sale 10b5-1 | −10,448 | $261.44 | $2.7M | 19,275 |
| 2025-03-18 | Wang Xiaodong Director | Sale 10b5-1 | −11,245 | $262.12 | $2.9M | 8,030 |
| 2025-03-18 | Wang Xiaodong Director | Sale 10b5-1 | −6,923 | $263.08 | $1.8M | 1,107 |
| 2025-03-18 | Wang Xiaodong Director | Sale 10b5-1 | −1,107 | $264.01 | $292K | 0 |
| 2025-03-18 | Wang Xiaodong Director | Option exercise · Share Option (Right to Buy) 10b5-1 | −542,880 | 1,628,647 | ||
| 2025-03-14 | Wu Xiaobin President, COO & GM China | Sale | −0 | 0 | ||
| 2025-03-11 | Wang Xiaodong Director | Gift | −158,717 | 5,082,165 | ||
| 2025-03-10 | OYLER JOHN Chief Executive Officer | Option exercise | +497,822 | $0.50 | $249K | 6,098,625 |
| 2025-03-10 | OYLER JOHN Chief Executive Officer | Option exercise | +41,210 | $6.50 | $268K | 41,210 |
| 2025-03-10 | OYLER JOHN Chief Executive Officer | Sale | −1,900 | $238.74 | $454K | 39,310 |
| 2025-03-10 | OYLER JOHN Chief Executive Officer | Sale | −6,800 | $239.59 | $1.6M | 32,510 |
| 2025-03-10 | OYLER JOHN Chief Executive Officer | Sale | −2,200 | $240.70 | $530K | 30,310 |
| 2025-03-10 | OYLER JOHN Chief Executive Officer | Sale | −7,069 | $241.92 | $1.7M | 23,241 |
| 2025-03-10 | OYLER JOHN Chief Executive Officer | Sale | −9,309 | $243.04 | $2.3M | 13,932 |
| 2025-03-10 | OYLER JOHN Chief Executive Officer | Sale | −5,313 | $244.04 | $1.3M | 8,619 |
| 2025-03-10 | OYLER JOHN Chief Executive Officer | Sale | −3,006 | $245.19 | $737K | 5,613 |
Page 28 of 71 · 1,406 trades